Flublok Quadrivalent Northern Hemisphere
- Product NDC
- 49281-720
- 11-digit product format
- 492810720
- Labeler code
- 49281
- Product ID
- 49281-720_4c51a757-868c-4cfe-a9a3-f138735badc5
- Type
- VACCINE
- Nonproprietary name
- INFLUENZA A VIRUS A/HAWAII/70/2019 (H1N1) RECOMBINANT HEMAGGLUTININ ANTIGEN, INFLUENZA A VIRUS A/MINNESOTA/41/2019 (H3N2) RECOMBINANT HEMAGGLUTININ ANTIGEN, INFLUENZA B VIRUS B/WASHINGTON/02/2019 RECOMBINANT HEMAGGLUTININ ANTIGEN, and INFLUENZA B VIRUS B/PHUKET/3073/2013 RECOMBINANT HEMAGGLUTININ ANTIGEN
- Dosage form
- INJECTION
- Route
- INTRAMUSCULAR
- Labeler
- Sanofi Pasteur Inc.
- Application
- BLA125285
- Marketing category
- BLA
- Marketing start
- 2020-07-02
- Marketing end
- 2021-06-30
- Substance
- INFLUENZA A VIRUS A/HAWAII/70/2019 (H1N1) RECOMBINANT HEMAGGLUTININ ANTIGEN; INFLUENZA A VIRUS A/MINNESOTA/41/2019 (H3N2) RECOMBINANT HEMAGGLUTININ ANTIGEN; INFLUENZA B VIRUS B/WASHINGTON/02/2019 RECOMBINANT HEMAGGLUTININ ANTIGEN; INFLUENZA B VIRUS B/PHUKET/3073/2013 RECOMBINANT HEMAGGLUTININ ANTIGEN
- Active strength
- 45 ug/.5mL; ug/.5mL; ug/.5mL; ug/.5mL
- NDC exclude flag
- No
- Listing certified through
- 0000-00-00
- Current FDA listing
- Historical FDA.report record
Purple Book Biologic Products#
BLA, Proprietary name, Proper name table| BLA | Proprietary name | Proper name | License type | Status | Latest source |
|---|
| 125285 | Flublok | Influenza Vaccine | 351(a) | Rx | 2026-06-01 |
Packages#
Package NDC, 11-digit format, Description table| Package NDC | 11-digit format | Description | Units | Marketing start | Marketing end | Sample | Exclude flag | Status |
|---|
| 49281-720-10 | 49281072010 | 10 SYRINGE in 1 CARTON (49281-720-10) > .5 mL in 1 SYRINGE (49281-720-88) | 10 syringe | 2020-07-02 | 2021-06-30 | No | No | Current |